Autopsy report · NCT00971503

Safety and Efficacy of Arterial Delivery of Autologous Bone Marrow Cells in the Treatment of Insulin-Dependent Diabetes

“Principal Investigator moved to Chile from Argentina”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of Moron

Sponsor type

University, hospital or other

Conditions

Type 1 Diabetes Mellitus

Interventions

autologous bone marrow implantation; Saline injection

Participants

34 (planned, not actual)

Sites

1

Countries

Chile

Trials that died the same way

• A Study of Oral L-citrulline in Sickle Cell Disease
  “Principal Investigator moved to another institution” (67% match in meaning)
• Dupilumab Phase 4 Study
  “Investigator moved from institution.” (66% match in meaning)
• A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease
  “Principal Investigator has moved to another institution” (65% match in meaning)
• Single-portal Endoscopic Carpal Tunnel Release Versus Knifelight for Carpal Tunnel Syndrome. A Randomized Control Trial
  “The principal investigator of the study relocated to another institution.” (63% match in meaning)
• Brain Function in Depression and Insulin Resistance
  “Principal Investigator Left University” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.